Atlas Trials

A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster

Clinical trial NCT05609045 · WITHDRAWN

Trial details

NCT number
NCT05609045
Sponsor
Wuhan Rhegen Biotechnology Co., Ltd.
Status
WITHDRAWN
Phase
Phase 1
Study type
INTERVENTIONAL
COVID-19 Pandemic
Start date
2023-06-01
Primary completion
2023-08-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.